Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10314550 | 0.89 | SMO (0.49) | SMOALDH1A1GAAMAPTNPC1 | |
| SCHEMBL1061851 | 0.88 | SMO (0.58) | SMOPDE4BNPC1RAB9A | |
| SCHEMBL10314595 | 0.87 | SMO (0.48) | SMOPDE4BALDH1A1GAAMAPT | |
| SCHEMBL10314562 | 0.86 | SMO (0.48) | SMOALDH1A1GAAMAPTNPC1 | |
| SCHEMBL1061487 | 0.86 | SMO (0.56) | SMOPDE4BALDH1A1GAAMAPT | |
| SCHEMBL10314574 | 0.86 | SMO (0.48) | SMOALDH1A1GAAMAPTNPC1 | |
| SCHEMBL12962752 | 0.85 | SMO (0.49) | SMOALDH1A1GAAMAPTNPC1 | |
| SCHEMBL12962751 | 0.84 | SMO (0.46) | SMOPDE4BALDH1A1GAAMAPT | |
| SCHEMBL12962755 | 0.82 | SMO (0.52) | SMOALDH1A1GAAMAPTDPP4 | |
| SCHEMBL10314554 | 0.82 | SMO (0.42) | SMOALDH1A1GAAMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217176-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | SMO 1/4885PDE4B 2413/4885ALDH1A1 745/4885 |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | SMO 1/4885PDE4B 2652/4885ALDH1A1 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.